272 related articles for article (PubMed ID: 27687480)
1. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Manasanch EE; de Larrea CF; Zingone A; Steinberg SM; Kwok M; Tageja N; Bhutani M; Kazandjian D; Roschewski M; Wu P; Carter G; Zuchlinski D; Mulquin M; Lamping L; Costello R; Burton D; Gil LA; Figg WD; Maric I; Calvo KR; Yuan C; Stetler-Stevenson M; Korde N; Landgren O
Leuk Lymphoma; 2017 Mar; 58(3):639-645. PubMed ID: 27687480
[TBL] [Abstract][Full Text] [Related]
2. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
[TBL] [Abstract][Full Text] [Related]
5. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
6. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F
Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
[TBL] [Abstract][Full Text] [Related]
9. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.
Sissung TM; Peer CJ; Korde N; Mailankody S; Kazandjian D; Venzon DJ; Landgren O; Figg WD
Cancer Chemother Pharmacol; 2017 Jul; 80(1):217-221. PubMed ID: 28488026
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Palumbo A; Obreja M; Aggarwal S; Moreau P
Br J Haematol; 2017 May; 177(3):404-413. PubMed ID: 28211560
[TBL] [Abstract][Full Text] [Related]
12. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
Kazandjian D; Korde N; Mailankody S; Hill E; Figg WD; Roschewski M; Landgren O
JAMA Oncol; 2018 Dec; 4(12):1781-1783. PubMed ID: 30477009
[TBL] [Abstract][Full Text] [Related]
13. Final results of a phase I study of carfilzomib, lenalidomide, and dexamethasone for heavily pretreated multiple myeloma.
Sugiura I; Suzuki K; Ri M; Chou T; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Iida S
Int J Hematol; 2020 Jan; 111(1):57-64. PubMed ID: 31664647
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.
Wester R; van der Holt B; Asselbergs E; Zweegman S; Kersten MJ; Vellenga E; van Marwijk Kooy M; de Weerdt O; Minnema M; Lonergan S; Palumbo A; Lokhorst H; Broijl A; Sonneveld P
Haematologica; 2019 Nov; 104(11):2265-2273. PubMed ID: 30948492
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
16. Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma.
Oldziej A; Bolkun L; Galar M; Kalita J; Ostrowska H; Romaniuk W; Kloczko J
Leuk Res; 2014 Aug; 38(8):925-30. PubMed ID: 24923860
[TBL] [Abstract][Full Text] [Related]
17. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.
Jakubowiak AJ; Dytfeld D; Griffith KA; Lebovic D; Vesole DH; Jagannath S; Al-Zoubi A; Anderson T; Nordgren B; Detweiler-Short K; Stockerl-Goldstein K; Ahmed A; Jobkar T; Durecki DE; McDonnell K; Mietzel M; Couriel D; Kaminski M; Vij R
Blood; 2012 Aug; 120(9):1801-9. PubMed ID: 22665938
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma.
Vandross A
Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma.
Mikhael JR; Reeder CB; Libby EN; Costa LJ; Bergsagel PL; Buadi F; Mayo A; Nagi Reddy SK; Gano K; Dueck AC; Stewart AK
Br J Haematol; 2015 Apr; 169(2):219-27. PubMed ID: 25683772
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Mushtaq A; Kapoor V; Latif A; Iftikhar A; Zahid U; McBride A; Abraham I; Riaz IB; Anwer F
Crit Rev Oncol Hematol; 2018 May; 125():1-11. PubMed ID: 29650268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
